FCCC LOGO Faculty Publications
Coit DG , Thompson JA , Albertini MR , Barker C , Carson WE , Contreras C , Daniels GA , DiMaio D , Fields RC , Fleming MD , Freeman M , Galan A , Gastman B , Guild V , Johnson D , Joseph RW , Lange JR , Nath S , Olszanski AJ , Ott P , Gupta AP , Ross MI , Salama AK , Skitzki J , Sosman J , Swetter SM , Tanabe KK , Wuthrick E , McMillian NR , Engh AM
Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
J Natl Compr Canc Netw. 2019 Apr 1;17(4) :367-402
Back to previous list
Abstract
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cutaneous melanoma have been significantly revised over the past few years in response to emerging data on immune checkpoint inhibitor therapies and BRAF-targeted therapy. This article summarizes the data and rationale supporting extensive changes to the recommendations for systemic therapy as adjuvant treatment of resected disease and as treatment of unresectable or distant metastatic disease.
Notes
Coit, Daniel G. Thompson, John A. Albertini, Mark R. Barker, Christopher Carson, William E., III Contreras, Carlo Daniels, Gregory A. DiMaio, Dominick Fields, Ryan C. Fleming, Martin D. Freeman, Morganna Galan, Anjela Gastman, Brian Guild, Valerie Johnson, Douglas Joseph, Richard W. Lange, Julie R. Nath, Sameer Olszanski, Anthony J. Ott, Patrick Gupta, Aparna Priyanath Ross, Merrick, I Salama, April K. Skitzki, Joseph Sosman, Jeffrey Swetter, Susan M. Tanabe, Kenneth K. Wuthrick, Evan McMillian, Nicole R. Engh, Anita M. 1540-1413 J Natl Compr Canc Netw. 2019 Apr 1;17(4):367-402. doi: 10.6004/jnccn.2019.0018.